|
|||||
|
|
| HIV-1 AE重组型疫苗构建及免疫原性研究 | |
| 引用本文： | 张聪优,万延民,仇超,黄杨,阮力,许雪梅,徐建青. HIV-1 AE重组型疫苗构建及免疫原性研究[J]. 疾病控制杂志, 2010, 14(9): 831-835 |
| 作者姓名： | 张聪优 万延民 仇超 黄杨 阮力 许雪梅 徐建青 |
| 作者单位： | 1. 中国医学科学院基础医学研究所北京协和医学院基础学院生物物理与结构生物学系,北京,100073;复旦大学附属上海市公共卫生临床中心,上海,201508 2. 复旦大学附属上海市公共卫生临床中心,上海,201508 3. 复旦大学生物医学研究院,上海,200032 4. 中国疾病预防控制中心病毒病预防控制所,北京,100050 5. 中国医学科学院基础医学研究所北京协和医学院基础学院生物物理与结构生物学系,北京,100073 6. 复旦大学附属上海市公共卫生临床中心,上海,201508;复旦大学生物医学研究院,上海,200032 |
| 基金项目： | 国家"十一五"重大科技专项课题，国家自然科学基金 |
| 摘 要： | 目的利用AE亚型的膜蛋白,研发抗HIV-1AE重组型的疫苗并进行免疫原性评价。方法构建表达中国流行株97CNGX2F（HIV-1 AE2F）包膜蛋白gp140的重组痘苗病毒rVVT140AE。使用表达gp140的DNA疫苗和rVVT140AE用初免-加强方式免疫小鼠。免疫结束后第2周处死小鼠,分别检测特异性抗体滴度和特异性T细胞反应。结果本疫苗所活化的特异性抗体滴度在3 200和51 200之间,几何平均值为11 143;总T细胞免疫反应强度为（1 918±442）SFCs/10^6脾细胞,其中针对env1、env2、env3、env4肽池的免疫反应强度分别为（1 280±330）SFCs/10^6脾细胞,（66±16）SFCs/10^6脾细胞,（163±34）SFCs/10^6脾细胞和（409±96）SFCs/10^6脾细胞,均显著高于空载体对照组（〈10 SFCs/10^6脾细胞）。结论本实验构建的HIV-1 AE2F株包膜蛋白gp140重组痘苗病毒疫苗可作为针对我国HIV-1流行株的候选疫苗免疫原。 |
| 关 键 词： | HIV疫苗 包膜蛋白 疫苗,合成 |
Construction and immunogenicity analysis of a vaccine against HIV-1 AE recombinant |
|
| ZHANG Cong-you,WAN Yan-min,QIU Chao,HUANG Yang,RUAN Li,XU Xue-mei,XU Jian-qing. Construction and immunogenicity analysis of a vaccine against HIV-1 AE recombinant[J]. Chinese Journal of Disease Control and Prevention, 2010, 14(9): 831-835 | |
| Authors: | ZHANG Cong-you WAN Yan-min QIU Chao HUANG Yang RUAN Li XU Xue-mei XU Jian-qing |
| Affiliation: | 1.Department of Biophysics and Structural Biology,Institute of Basic Medical Sciences,Chinese Academy of Medical Sciences and School of Basic Medicine,Peking Union Medical College,Beijing 100073,China;2.Shanghai Public Health Clinical Center Affiliated to Fudan Univeristy,Shanghai 201508,China;3.Insistutes of Biomedical Sciences,Fudan University,Shanghai 200032,China;4.Insistute for Viral Disease Control and Prevention,Chinese Center for Disease Control and Prevention,Beijing 100050,China ) |
| Abstract: | Objective To develop an HIV-1 AE recombinant envelope based vaccine since this recombinant has been accounted for high percent of sexual transmitted HIV-1 prevalence.Methods A recombinant Tiantan vaccinia based vaccines rVVT140AE expressing envelope gp140 from a circulating recombinant clade 97CNGX2F（HIV-1 AE2F） was constructed.DNA vaccine expressing gp140 and rVVT140AE was used to immunize mice with a prime/boost strategy.Mice were sacrificed 2 weeks after the final inoculation,then specific antibody titer and T cell responses were measured separately.Results The titers of env-specific antibodies elicited by this vaccines ranged from 3 200 to 51 200,with an geometric average at 11 143.Total T cell responses measured by ELISPOT was（1 918±442） SFCs/106 splenocytes with the responses against four peptide pools env1,env2,env3,env4 at（1 280±330） SFCs/10^6 splenocytes,（66±16） SFCs/10^6 splenocytes,（163±34） SFCs/10^6 splenocytes and（409±96） SFCs/10^6 splenocytes,which were all significantly higher than mock control group（〈10 SFCs/10^6 splenocytes）.Conclusions The HIV-1 AE2F envelope gp140 recombinant vaccinia virus vaccine can be used for HIV-1 strains candidate vaccine immunogen. |
| Keywords: | HIV vaccine Envelope protein Vaccines synthetic |
| 本文献已被 维普 万方数据 等数据库收录！ | |